Page 14 - Resistant Solution News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Resistant solution. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Resistant Solution Today - Breaking & Trending Today

atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression

NEW YORK and BERLIN, Jan. 06, 2023 (GLOBE NEWSWIRE) atai Life Sciences (NASDAQ: ATAI) ("atai" or "the Company"), a clinical-stage biopharmaceutical company focused on mental health, announced that, ....

New York , United States , Allan Malievsky , Exchange Commission , Perception Neuroscience Inc , Company Contact , Life Sciences , Securities Exchange , Otsuka Pharmaceutical Co Ltd , Perception Neuroscience , Depression Rating Scale , Florian Brand , Study Design , Clinician Administered Dissociative States Scale , Modified Observer , Sedation Scale , New York City Based , Private Securities Litigation Reform Act , Securities Act , Securities Exchange Act , Annual Report , Quarterly Reports ,

KBP Biosciences: Ocedurenone (KBP-5074) Featured at ASN Kidney Week: Ocedurenone is a Potential New Treatment Option for Patients with Uncontrolled or Resistant Hypertension and Advanced CKD

Hepatic Impairment and Drug-Drug Interaction Study Results Presented PRINCETON, N.J., Jan. 6, 2023 /PRNewswire/ KBP Biosciences PTE. Ltd. ("KBP Biosciences" or the "Company"), a clinical-stage ....

United States , San Antonio , Kostenloser Wertpapierhandel , James Mccabe , University Of Chicago Medical Center , American Heart Association Comprehensive Hypertension Center , American Heart Association Scientific Sessions , Renal Associates , University Of Michigan , Hepatic Impairment , Drug Interaction Study Results , Pablo Pergola , Mineralocorticoid Receptor Blocker , Uncontrolled Hypertension , American Heart Association , Comprehensive Hypertension Center , Chicago Medical Center , Drug Interaction , Moderate Hepatic , Deputy Chief Medical , Julia Yang , Chief Operations Officer , Bertram Pitt , Fred Yang Phd , Chief Development Officer , Moderate Hepatic Impairment ,

S2Medical AB: Positive outcome when S2Medicals antimicrobial peptides were tested against the multi resistant bacteria that by WHO have been defined as a global health threat

LINKÖPING, Sweden, Jan. 2, 2023 /PRNewswire/ Scientists from the HeAliX-project which the Company is a part of have evaluated the antimicrobial effect from the peptide technology that the ....

Petter Sivl , University Of Technology , Abuse Regulation ,

Merck & Co., Inc.: LYNPARZA (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer

First PARP inhibitor and new hormonal agent combination approved for these patients in Europe AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced ....

United States , Julie Cunningham , Peter Dannenbaum , Damini Chokshi , Michael Mcardle , European Commission , Statement Of Merck Co Inc , Prostate Cancer Working Group , Merck Co Inc , Exchange Commission , Committee For Medicinal Products Human , European Union , Medicinal Products , Human Use , Acute Myeloid Leukemia , Thromboembolic Events , Fetal Toxicity , First Line Maintenance , Advanced Ovarian Cancer , First Line Maintenance Advanced Ovarian Cancer , Maintenance Recurrent Ovarian Cancer , Adjuvant Treatment , High Risk Early Breast Cancer , Negative Metastatic Breast Cancer , Metastatic Pancreatic Adenocarcinoma , Metastatic Castration Resistant Prostate Cancer ,

Price reduction for expanding access to highly effective MDR tuberculosis treatment

Pretomanid, used within the BPaL and BPaLM regimens, is already being piloted and implemented in operational research programmes run by government agencies and civil society organisations ....

Pretomanid Pa , Tb Alliance , National Tuberculosis Elimination Program , World Health Organisation , Drug Controller General ,